Skip to search formSkip to main contentSkip to account menu

mofezolac

Known as: (3,4-bis(4-methoxyphenyl)-5-isoxazolyl)acetic acid, (3,4-di-(4-methoxyphenyl)-5-isoxazolyl)acetic acid, 3,4-DMPIAA 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
BACKGROUND/AIMS We have previously shown that long-term consumption of 10% beef tallow diet promotes colon carcinogenesis in both… 
2004
2004
AbstractObjective and design:The aim of this study was to confirm the involvement of cyclooxygenase (COX)-1 in rheumatoid… 
1990
1990
Pharmacological activities of mofezolac were investigated in experimental animal models and compared with those of indomethacin… 
1990
1990
Mofezolac (N-22) is a newly developed analgesic and anti-inflammatory agent. The acute toxicities of N-22 were investigated in… 
1990
1990
The chronic toxicity study of mofezolac (N-22), a new developed analgesic and anti-inflammatory agent, was carried out in beagle… 
1990
1990
Mofezolac (N-22) is a new developed analgesic and anti-inflammatory agent. A subacute oral toxicity test of N-22 was carried out… 
1990
1990
In vivo metabolism of[3, 4-di(4-methoxyphenyl)-5-isoxazolyl]acetic acid (mofezolac) was studied in mice, rats, dogs and monkeys… 
1990
1990
A three-month oral subacute toxicity study of mofezolac (N-22), a non-steroidal anti-inflammatory agent, was performed using dose… 
1990
1990
Mofezolac (N-22) is a new developed analgesic and anti-inflammatory agent. A teratogenicity study of N-22 was carried out in New… 
1990
1990
Fifty two-week oral toxicity study of mofezolac (N-22), a new developed analgesic and anti-inflammatory agent, was carried out in…